WO2014183300A1 - Inhibiteurs de tyrosine kinase vegfr - Google Patents

Inhibiteurs de tyrosine kinase vegfr Download PDF

Info

Publication number
WO2014183300A1
WO2014183300A1 PCT/CN2013/075813 CN2013075813W WO2014183300A1 WO 2014183300 A1 WO2014183300 A1 WO 2014183300A1 CN 2013075813 W CN2013075813 W CN 2013075813W WO 2014183300 A1 WO2014183300 A1 WO 2014183300A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
phenyl
alkyl
compounds
prepared
Prior art date
Application number
PCT/CN2013/075813
Other languages
English (en)
Inventor
Jing Ling
Jinyong LIU
Original Assignee
Suzhou Vivotide Biotechnologies Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Vivotide Biotechnologies Co., Ltd. filed Critical Suzhou Vivotide Biotechnologies Co., Ltd.
Priority to PCT/CN2013/075813 priority Critical patent/WO2014183300A1/fr
Publication of WO2014183300A1 publication Critical patent/WO2014183300A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés, leurs promédicaments et leurs sels pharmaceutiquement acceptables, ainsi que des compositions pharmaceutiques contenant de tels composés utiles pour le traitement de certaines maladies modulées par l'inhibition des récepteurs à activité tyrosine kinase des facteurs de croissance de l'endothélium vasculaire (VEGF). L'invention concerne en particulier des composés et des compositions, et des procédés pour la prophylaxie, la gestion et le traitement de cancers par l'inhibition des récepteurs à activité tyrosine kinase des VEGF.
PCT/CN2013/075813 2013-05-17 2013-05-17 Inhibiteurs de tyrosine kinase vegfr WO2014183300A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/075813 WO2014183300A1 (fr) 2013-05-17 2013-05-17 Inhibiteurs de tyrosine kinase vegfr

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/075813 WO2014183300A1 (fr) 2013-05-17 2013-05-17 Inhibiteurs de tyrosine kinase vegfr

Publications (1)

Publication Number Publication Date
WO2014183300A1 true WO2014183300A1 (fr) 2014-11-20

Family

ID=51897613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/075813 WO2014183300A1 (fr) 2013-05-17 2013-05-17 Inhibiteurs de tyrosine kinase vegfr

Country Status (1)

Country Link
WO (1) WO2014183300A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402869A (zh) * 2014-12-04 2015-03-11 常州费洛斯药业科技有限公司 一种小分子抑制剂化合物、其制备方法及用途
CN104844526A (zh) * 2015-04-16 2015-08-19 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
WO2016138527A1 (fr) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de kinase, et leurs applications thérapeutiques
KR20160147170A (ko) * 2015-06-12 2016-12-22 중앙대학교 산학협력단 신규 파조파닙 유도체 및 이를 함유하는 약학조성물
WO2020135489A1 (fr) * 2018-12-26 2020-07-02 上海喆邺生物科技有限公司 Dérivés de 2,4-diaminopyrimidine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101659659A (zh) * 2008-08-29 2010-03-03 和记黄埔医药（上海）有限公司 嘧啶衍生物及其医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101659659A (zh) * 2008-08-29 2010-03-03 和记黄埔医药（上海）有限公司 嘧啶衍生物及其医药用途

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402869A (zh) * 2014-12-04 2015-03-11 常州费洛斯药业科技有限公司 一种小分子抑制剂化合物、其制备方法及用途
CN107708690A (zh) * 2015-02-27 2018-02-16 南特生物科学公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
CN107635553A (zh) * 2015-02-27 2018-01-26 南特生物科学公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
WO2016137506A1 (fr) 2015-02-27 2016-09-01 Nantbioscience, Inc. Dérivés de pyrimidine comme inhibiteurs de kinase et applications thérapeutiques associées
CN107708690B (zh) * 2015-02-27 2021-09-14 常山凯捷健生物药物研发（河北）有限公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
JP2018506564A (ja) * 2015-02-27 2018-03-08 ナントバイオサイエンス、インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体及びその治療用途
KR20170122781A (ko) * 2015-02-27 2017-11-06 난트바이오사이언스 인코포레이티드 키나아제 억제제로서의 피리미딘 유도체 및 그의 치료적 용도
WO2016138527A1 (fr) * 2015-02-27 2016-09-01 Nantbioscience, Inc. Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de kinase, et leurs applications thérapeutiques
US10766879B2 (en) 2015-02-27 2020-09-08 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
CN107635553B (zh) * 2015-02-27 2020-08-14 常山凯捷健生物药物研发（河北）有限公司 作为激酶抑制剂的嘧啶衍生物和它们的治疗应用
JP2018506565A (ja) * 2015-02-27 2018-03-08 ナントバイオサイエンス、インコーポレイテッド キナーゼ阻害剤としてのピリミジン誘導体及びその治療用途
KR102008082B1 (ko) 2015-02-27 2019-08-06 난트바이오 인코포레이티드 키나아제 억제제로서의 피리미딘 유도체 및 그의 치료적 용도
RU2701188C2 (ru) * 2015-02-27 2019-09-25 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения
AU2016224969B2 (en) * 2015-02-27 2019-10-31 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
RU2718915C2 (ru) * 2015-02-27 2020-04-15 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназ и их терапевтические применения
AU2015383881B2 (en) * 2015-02-27 2021-01-28 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
CN104844526A (zh) * 2015-04-16 2015-08-19 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
KR101705980B1 (ko) * 2015-06-12 2017-02-13 중앙대학교 산학협력단 신규 파조파닙 유도체 및 이를 함유하는 약학조성물
KR20160147170A (ko) * 2015-06-12 2016-12-22 중앙대학교 산학협력단 신규 파조파닙 유도체 및 이를 함유하는 약학조성물
WO2020135489A1 (fr) * 2018-12-26 2020-07-02 上海喆邺生物科技有限公司 Dérivés de 2,4-diaminopyrimidine

Similar Documents

Publication Publication Date Title
TWI484960B (zh) 嘧啶衍生物
TW202019900A (zh) Ptpn11抑制劑
CA2914525C (fr) Quinazolines substituees par une sulfoximine pour les compositions pharmaceutiques
CN105473581A (zh) 作为溴结构域抑制剂的新取代的双环化合物
BR112012011287A2 (pt) compostos inibidores de cinase, sua formulação farmacêutica e seus usos
NO324471B1 (no) Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning
WO2014183300A1 (fr) Inhibiteurs de tyrosine kinase vegfr
BR112019011044A2 (pt) compostos pirazol substituídos e métodos de uso no tratamento de doenças hiperproliferativas
CN111386266B (zh) 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物
CN104395308A (zh) N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-吡喃-4-基氨基)-苯甲酰胺的制备方法
WO2011072791A1 (fr) Inhibiteurs de la sphingosine kinase
Jeankumar et al. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors
JP2020529968A (ja) 置換５員および６員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
CN102459252A (zh) 用于治疗糖原合酶激酶3相关疾病诸如阿尔茨海默病的咪唑取代的嘧啶
BR112019009432A2 (pt) compostos de pirimidina ou sal famaceitucamente aceitável, método de preparo dos mesmos, e composição farmacêutica e comida funcional saudável
US11446299B2 (en) Carbazole EHop-016 derivatives as anticancer and anti-migratory agents
CN108929312A (zh) 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CZ20032659A3 (cs) Benzimidazoly, které jsou účinné při léčení sexuální dysfunkce
EP3544965A1 (fr) Composés de sulfoximine, de sulfonimidamide, de sulfondiimine et de diimidosulfonamide en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase
CA3131285A1 (fr) Inhibiteur d'interaction proteine-proteine d'aniline wdr5, son procede de preparation et son utilisation
WO2016205534A1 (fr) Inhibiteurs de ptp4a3 pour le traitement du cancer
KR20180032784A (ko) 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9642851B2 (en) Indolinone derivative as tyrosine kinase inhibitor
BR112019022331A2 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos como inibidores de di-hidro-orotato oxigenase
WO2015074124A1 (fr) Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13884937

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/04/2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13884937

Country of ref document: EP

Kind code of ref document: A1